Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …
To evaluate the feasibility and effectiveness of vaginal ethanol sclerotherapy (EST) for ovarian endometriomas, with a focus on recurrence and subsequent fertility outcomes.
A biopsychosocial approach serves as an important paradigm underpinning musculoskeletal pain education training. Understanding how educators teach this approach in their training may provide insights on how to improve the …
Endometriosis (EMS) causes debilitating pain and reduces quality of life. Whether pelvic floor muscle training (PFMT) provides independent, additive benefits beyond standard postoperative hormonal suppression remains unknown.
Endometriosis (EuE) is a chronic, incurable disease. Due to limited efficacy, high recurrence rates, and serious side effects of current treatments, development of new, targeted, nonhormonal therapies is urgently needed. …
Endometriosis is a chronic, estrogen-dependent inflammatory condition affecting approximately 10% of women of reproductive age and manifesting with pelvic pain, dysmenorrhea, dyspareunia, fatigue, and infertility. First-line treatment in most patients …
Rectal endometriosis is among the most symptomatic forms of the disease. When hormonal therapy fails, surgery is often required. High-intensity focused ultrasound (HIFU) is widely used in gynecology for the …
Chronic pelvic pain syndrome (CPPS) encompasses a heterogeneous group of debilitating conditions including interstitial cystitis/bladder pain syndrome (IC/BPS), chronic abacterial prostatitis, endometriosis, and pelvic congestion syndrome, among others. Despite advances …
Endometriosis is a chronic, systemic gynecological disorder that affects 190 million women worldwide. Current treatments consist of hormonal suppression and surgical excision; however, both have considerable side effects and a …
Premature ovarian insufficiency (POI) is defined as loss of ovarian function before the age of 40 years. It has a profound impact on patients' quality of life, particularly due to …